Navigation Links
Calithera Biosciences Closes $40 Million in Series A Financing
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million.  Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round.  The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.  

"Promoting apoptosis in cancer cells is a validated approach to the treatment of cancer, as many oncology drugs on the market today are known to kill tumor cells by activating apoptotic pathways, albeit through indirect means," said Susan Molineaux, Ph.D., co-founder and Chief Executive Officer of Calithera.  "By targeting caspases directly, we hope to develop agents that have broad utility across many types of cancer, with greater specificity than current treatments and the potential to overcome chemoresistance."

Calithera's technology was developed by and licensed from the laboratory of co-founder James Wells, Ph.D., chair of the Department of Pharmaceutical Chemistry in the University of California, San Francisco School of Pharmacy.  Dr. Wells's laboratory has successfully identified several novel compounds that selectively activate procaspases and trigger apoptosis in cancer cells.  Proceeds from the financing will be used to advance one or more caspase activators through preclinical development and into Phase 1 clinical trials in cancer patients.  In parallel, the company will ex
'/>"/>

SOURCE Calithera Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015  Alere Inc. (NYSE: ALR ... the White House Antibiotic Stewardship Forum today to ... and advance the President,s National Action Plan to ... number of measurable goals and objectives over the ... healthcare providers protect their patients through antibiotic stewardship, ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. ... the Moenninghoff product line . , ... announce that the R.M. Hoffman Company will be representing ... in 1916, this is a strategically important step. ... of professional distributor we need to successfully grow our ...
(Date:6/1/2015)... 2015 Chosen for his engaging ... Uldrich has been selected as keynote speaker for ... He will deliver his keynote: "Don't Stop Thinking ... presentations to the American Medical Association, Blue Cross ... Alcetel-Lucent/Verizon Forum on Wireless Healthcare, United Healthcare, IASIS ...
Breaking Biology Technology:Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2
... for 15 minutes, couldn't imagine the influence the Internet, blogging, social ... these tools, everyone can have their 15 minutes - but just ... is about all anyone has time for these days, at least ... reminded of this after coming back from a near three-week holiday ...
... the lead cancer drug candidate of Madison's Quintessence Biosciences ... Food and Drug Aministration for being tested on cancer ... meeting of the American Association for Cancer Research , ... scale and applied in safe doses, the company announced. , ...
... Madison, Wis . - Mithridion, Inc ., a biopharmaceutical ... of Alzheimer's disease, has closed an additional $1.2 million of ... , ,The latest round of funding brings the total equity ... above the company's initial funding target. Mithridion will use the ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... a remote region of the Russian mountains a previously unknown ... Lead Scientist Professor Hans Cornelissen and his Russian-Dutch team describe ... root belongs to the small alpine plant Corydalis conorhiza and ... through layers of snow. Given this novel behaviour, the scientists ...
... In a study published in the open-access, peer-reviewed ... Han and Piotr Jablonski at Seoul National University, Korea, ... their genitalia from males, forceful copulatory attempts, females of ... the evolutionary arms race between the sexes. Instead, females ...
... are acclaimed in representing natural climate archives. For ... of these annual rings depend mainly on temperature and ... seasonal variations, the correlation is not so evident. ... Geosciences and their colleagues of the Australian National University ...
Cached Biology News:Newly discovered snow roots are 'evolutionary phenomenon' 2Hidden genitalia in female water striders makes males 'sing' 2Australia's climate: Drought and flooding in annual rings of tropical trees 2
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... Immunogen: Synthetic peptide derived from an internal ... (Mammalian target of rapamycin FRAP RAFT1 RAPT1). ... protein. On Western blots it identifies ... Reactivity: Human (positive control: HEK293 cell lysates). ...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
...
Biology Products: